In ALK+ ALCL, the JAK/STAT pathway is a critical downstream mediator of ALK oncogenic signaling sustaining the neoplastic phenotype and contributing to the survival of lymphoma cells (18, 19); therefore, we investigated whether oncogenic ALK affected CD45 expression and activity. This evidence concerns the gene ALK and lymphoma.